Orkuturlar et al. (2018) evaluated 40 subjects with BC and 33 women as controls, demonstrating that serum concentrations of PON1 and arylesterase (ARE) were significantly lower in those subjects who required neoadjuvant chemotherapy [22]. Here, PON1 is linked to breast cancer.